Roche's Collaborator MediLink Announces Phase III Data for Tam-Peli Showing Significantly Improved Overall Survival in Chinese Patient Population With Relapsed Small-cell Lung Cancer
September 15, 2026
September 15, 2026
BASEL, Switzerland, Sept. 15 (TNSxrep) -- Roche, a biotech company, issued the following news release:
* * *
Roche's collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
* Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death . . .
* * *
Roche's collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
* Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death . . .